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Human pregnancy is known to predispose women to disproportionate morbidity and mortality 
from influenza infection.  Limited investigation has been performed to understand the 
mechanism(s) of increased risk.  Investigation of a pregnant ferret model was undertaken using 
aerosolized 2009 pH1N1 influenza.  Pregnant ferrets demonstrated worse clinical disease and 
increased pro-inflammatory cytokine gene expression levels, notably IL-6 and IL-10 in the lung 
and at the maternal/fetal interface but not the spleen. Influenza virus was detected by semi-
quantitative RT-PCR in many tissues including the placenta and kits but not the uterus of the 
non-pregnant ferrets, suggesting placental-fetal transmission. No obvious difference in lung 
pathology was observed between the pregnant and age-matched controls. Further model 
development is warranted to elucidate mechanisms that cause greater disease during pregnancy 
and effects of maternal disease on fetal outcomes. Ultimately, this model would further aid in 
investigating countermeasures against influenza during pregnancy. The public health 
significance of this study is that by establishing a pertinent influenza pregnant animal model, 
answers to translational questions about the effectiveness of therapeutics and when treatment 
would be most effective could be investigated, potentially lowering the amount of lives lost, 
hospitalization rates, and economic burden caused by this health disparity. 
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1.0  INTRODUCTION 
1.1 VIRAL ORIGINS OF PANDEMIC H1N1 
Influenza A virus is a zoonotic pathogen that continuously circulates through animal 
hosts, such as humans, birds, horses, dogs and pigs1,2. This virus has a segmented, negative-
sense, single stranded RNA genome that typically encodes 11-12 proteins1,3. Generally it is 
thought that simultaneous infection of a single cell by two distinct influenza A viruses can cause 
reassortment of genes and result in the generation of a novel influenza strain, which can lead to 
human pandemics1,3.  
Typically, influenza A viruses are subtyped based on their hemagglutinin (HA) and 
neuraminidase (NA) glycoproteins4. Currently, there are virus strains from 16 HA subtypes and 
nine NA subtypes circulating in birds, and two virus subtypes circulating in humans1. Evolution 
of human seasonal influenza typically undergoes antigenic drift characterized by point mutations 
in the HA and NA glycoproteins, necessitating a new yearly influenza vaccine and causing 
yearly epidemics. Larger changes in the HA subtype, typically caused by reassortment of two 
strains results in antigenic shift and the emergence of novel strains that can cause devastating 
pandemics2. 
In April 2009, a novel H1N1 influenza A virus infected humans, possibly originating 
from a domestic pig population in Mexico5–7. By the end of April, the World Health 
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Organization (WHO) had issued a Global Outbreak Alert as a result of laboratory-confirmed 
human cases of swine influenza A/H1N1 in the USA and Mexico. Two months later, the U.S. 
Centers for Disease Control and Prevention (CDC) and WHO declared this outbreak of swine 
H1N1 influenza a pandemic.  The genome of pandemic H1N1 2009 (pH1N1) had never been 
previously seen in humans but there is evidence its’ predecessor circulated in pigs for years prior 
to its initial zoonotic transmission6. 
1.2 EPIDEMIOLOGY OF PANDEMIC H1N1 
Pandemic H1N1 emerged in early April 2009 in Vera Cruz, Mexico, quickly spreading to 
California and later, worldwide8. The emergence of 2009 pH1N1 came as a surprise because no 
surveillance is currently conducted in Mexico’s domestic pig population9.  By April 2010, over 
214 countries reported laboratory-confirmed A (H1N1) 2009 cases10. Most countries in the 
southern hemisphere immediately reported an increase in pandemic influenza compared to 
seasonal strains, but this happened more gradually in northern hemisphere countries11. Between 
April 2009 and August 2010, it has been estimated that 1-3 billon people worldwide were 
infected (15-45% of the world’s population)12. Mathematical models estimate that over 201,000 
respiratory deaths and 83,000 cardiovascular deaths were associated with pH1N1 globally12.  
In the United States, an estimated 61 million cases of pH1N1 resulted in approximately 
274,000 hospitalizations and 12,470 deaths, primarily occurring in individuals with underlying 
medical conditions12,13. However, unlike most influenza seasons where the burden and severity 
occurs among older individuals, a unique characteristic of pH1N1 was the shifting of the burden 
of disease to children and young adults10. Children under the age of 5 had the highest rate of 
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severe disease leading to hospitalization9. It has been suggested that older age groups may have 
been exposed to a genetically similar virus previously, and had developed partial immunity14, 
Subsequent seroprevalence studies demonstrated that 33% of humans over the age of 60 years 
old had cross-reactive antibodies to pH1N115.  
Pregnant women, especially those in their second and third trimesters, were also 
disproportionately affected. Estimates suggest that one third of all pregnant women in the US 
with confirmed pH1N1 were hospitalized, with their most common symptom being acute 
respiratory distress often requiring mechanical ventilation16. Of pregnant women hospitalized in 
the US, 23.3% were admitted to the intensive care unit (ICU) and 8% died16,17. At any given 
time, pregnant women make up approximately 1% of the US population, but during the 
pandemic, they accounted for 6.3% of general hospitalizations, 5.9% of ICU admissions, and 
5.7% of deaths, underscoring that pregnant women were disproportionately affected17.  Preterm 
delivery was also commonly reported, exceeding 30% when compared to a baseline level of 
9.6%17.  Many of the neonates did require hospitalization, but this was largely due to preterm 
birth, and not due to transmission of influenza. Among 45 infants tested by various methods of 
influenza detection in different locations, only 6 positive tests were reported, suggesting a small 
likelihood of fetal transmission17.  
1.2.1 Influenza Vaccine and Treatment 
The influenza vaccine is considered to be one of the most important tools for preventing 
the spread, and mitigating the impact, of influenza morbidity and mortality18,19.  Children aged 6 
months to 4 years had the highest vaccine coverage rate at 33%20.  The CDC strongly 
recommended vaccination for individuals afflicted with high-risk conditions, health care 
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personnel, pregnant women, and adults caring for children under the age of 6 months.19. Even 
with these highly publicized recommendations, only an estimated 46% of pregnant women, 12% 
of those with high-risk conditions, and 22% of health care personnel received the H1N1 vaccine 
by early January 2010 in the US20.  
The predominate immunogen in the inactivated vaccine is the hemmaglutinin (HA) and 
neuraminidase (NA) molecule of the different strains included in the influenza vaccine21. 
Different formulations of the trivalent influenza vaccine (TIV) are available, including the 
whole, split (chemically disrupted), or subunit (purified surface glycoprotein) vaccines, and 
generally includes the two most recent circulating strains of Influenza A and one Influenza B 
circulating strain. Deciding which formulation to administer is dependent on age, risk factors, 
and geographical location. The live attenuated influenza vaccine (LAIV) uses an attenuated cold-
adapted viral backbone of the HA and NA of the target strains18.  
The response elicited by the influenza vaccine is primarily antibody mediated. Usually 
within two weeks, vaccine recipients have established protective antibody titers against the 
specific HAs and NAs of the vaccine strains18. Antibodies generated against the HA molecule 
are thought to be the major correlate of vaccine protection, whereas the NA-specific antibodies 
aid in reducing the severity of infection. For the TIV vaccine, the serum antibody response 
consists mainly of influenza-specific IgG1 antibodies, with lower but detectable amounts of IgM 
and IgA antibodies22. The split-virus TIV induces the production of antibodies that primarily 
target the HA and NA glycoprotein, but antibodies directed against internal viral proteins, M and 
NP, can also be detected. While cell-mediated responses appear to play a role in recovery from 
influenza infection, conclusive evidence that these responses significantly contribute to 
preventing infection via vaccination is still lacking. The LAIV, administered intranasally, has a 
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slightly lower systemic humoral response when compared to the TIV, but induces a more robust 
secretory response, with greater production of SIgA22. LAIV has been shown to produce a 
cellular immune response, but this hasn’t been thoroughly explored.  
Pandemic H1N1 was susceptible to the neuraminidase inhibitors, oseltamivir and 
zanamivir, but resistant to amantadine23. NA inhibitors prevent the virus from effectively 
budding from the host cell3. Amantadine sterically blocks the M2 channel of influenza A, 
preventing uncoating of the virus. Unfortunately, the therapeutic use of amantadine was 
discontinued in 2009 due to all circulating strains developing resistance against the drug23.  
Treatment with NA inhibitors was found to be efficacious if given within 36 hours post onset of 
symptoms during the pH1N124. During the pandemic, the US Food and Drug Administration 
(FDA) issued an emergency authorization for the use of oseltamivir in infants under 1 year of 
age10.  
1.3 PATHOGENESIS 
1.3.1 Clinical Features 
Influenza typically presents with clinical signs such at fever, myalgia, malaise, headache 
and upper respiratory symptoms that include cough, sore throat, and rhinitis24. The spectrum and 
severity of clinical presentation varies by current health status, age, vaccination status, and is 
dependent on strain of virus. Pandemic H1N1 was initially considered a mild, self-limiting upper 
respiratory tract illness, much like that of the seasonal influenza.  However, in a subset of the 
population, pH1N1 caused more severe pulmonary symptoms, possibly due to its receptor 
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tropism for 2,3-linked sialic acid linkages located in the deep respiratory tract, as opposed to 
seasonal influenza which typically binds to 2,6-linked sialic acid receptors in the upper 
respiratory tract25. 
The virus is typically spread by airborne transmission or direct contact with an infected 
person or animal. The incubation period is short, usually lasting only two days, followed by the 
abrupt onset of symptoms of an illness that typically lasts no longer than a week. A small 
percentage of patients develop complications from influenza infection, which include 
pneumonia, bronchitis, sinitus, rarely encephalitis, transverse myelitis, Reye syndrome, 
myocarditis and pericarditis. These complications frequently cause more than 90% of flu-related 
fatalities among the elderly24. 
1.3.2 Cytokines 
The innate immune system is the first line of defense against invading viruses. In 
response to influenza infection, the innate immune system produces a pro-inflammatory and 
antiviral response in the form of cytokines and chemokines. Chemokines and cytokines play a 
major role in the pathogenesis of viral infections. Highly virulent strains of influenza viruses, 
such as avian H5N1 influenza, are known to cause aberrant and excessive cytokine production, 
resulting in higher levels of morbidity and mortality for humans and other mammals26,27. 
Increased levels of specific inflammatory cytokines, including tumor necrosis factor (TNF) α, 
interleukin 1 (IL-1), IL-6, IL-8, IL-12, interferon (IFN) γ, and IFN-α have been linked to disease 
progression and death in seasonal outbreaks of influenza26,27. Retrospective studies of patients 
severely infected with pH1N1 have identified a strong correlation with high sera levels of IL-6 
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and IL-1028. The underlying mechanism of how, or why, aberrant cytokine responses are 
correlated with more severe outcomes of influenza infection is unknown.   
1.4 IMMUNOLOGY OF PREGNANCY 
One of the most complex puzzles in modern immunology involves the “paradox of 
pregnancy”, where the mother must simultaneously tolerate the paternal derived fetal antigens 
while defending the fetus and herself against infection29. Historically, it was thought that 
pregnancy was an immunologically suppressed state that led to increased infectious disease 
susceptibility. More recent evidence indicates that there is an immune modulatory state, where 
during pregnancy, the immune system responds differentially depending on a combination of 
factors29. These factors include the type of microorganism, the stage of pregnancy, the response 
of the fetal-placental unit, and maternal immune response.  
Overall, there is evidence to suggest that the maternal immune system tolerates fetal 
antigens by suppressing cell-mediated immunity and maintaining humoral immunity.  However, 
this may be an over simplification30. Rather than looking at the immunology of pregnancy as a 
singular condition, it is more prudent to consider it as three distinct phases that influence and 
shape the maternal immune response29,31. During the first phase, in the first trimester, the 
maternal immune system is thought to be pro-inflammatory, resulting in a T-helper type 1 (Th-1) 
response. The second phase, during the second trimester, is an anti-inflammatory phase that 
results in a T-helper type 2 (Th-2) response. During the third phase and trimester, the maternal 
immune system is thought to switch back to the pro-inflammatory cytokine response to promote 
delivery. This Th1-Th2 shift programs not only the placental-fetal response, but also the 
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systemic maternal response from an initial cell-mediated response, to a humoral response, when 
confronted with infection.   
Adding to the complexity of the “paradox of pregnancy” is a new paradigm that proposes 
that the immunological response of the mother is not solely determined by the maternal response, 
but is also influenced by the fetal-placental unit29. Therefore, the immunology of pregnancy is 
the consequence of a combination of signals and responses from both the maternal and the fetal-
placental immune system. Results from laboratory studies have suggested that the type of 
response initiated at the placenta might influence the immunological response of the mother. If 
the viral infection elicits pro-inflammatory cytokines, such as interferon (IFN gamma), 
interleukin 12 (IL-12), and high levels of IL-6 at the placenta, it may, in turn, overstimulate the 
maternal immune system and lead to adverse pregnancy outcomes29,32. Alternatively, if a viral 
infection triggers a mild inflammatory response in the placenta, it may activate the maternal 
immune system to protect the fetus from harm.   
Consequently, pregnant women are not thought to be immunocompromised but instead 
experience significant immunologic changes during the course of pregnancy that may lead them 
to be more susceptible or more severely affected by infectious diseases. There is evidence for 
increased susceptibility to infectious diseases. For example, Listeria monocytogenes, an often 
invasive foodborne illness, is far more common during pregnancy, making up one third of all 
reported cases and resulting in a substantial amount of stillbirths33,34. Pregnant women are also 
far more likely to develop clinical signs of leprosy from Mycobacterium leprae, which is 
hypothesized to be the result of decreased cell-mediated immunity33. In addition to the increased 
susceptibility to certain infectious diseases, there is more evidence indicating that during 
pregnancy, there is a higher risk for developing increased disease severity. For instance, varicella 
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zoster infection occurring during pregnancy is more severe and can lead to varicella 
pneumonia33. It has been well documented that pregnant women experience a more severe 
clinical course, increased complication rates, and higher-case fatality rates during influenza 
pandemics33.  
As discussed above, changes in immune function over the course of pregnancy can alter a 
pregnant woman’s susceptibility to, and severity of, certain infectious diseases. The mechanisms 
by which pregnant women have untoward outcomes to infectious agents have not been well 
explored, particularly in basic bench research. To better understand the dynamics of the immune 
system during pregnancy and how it modifies and interacts with infectious agents, it is essential 
to develop new methodologies and relevant animal models of pandemic influenza infection. This 
knowledge will help address challenging questions about why pregnant women are more 
susceptible to, or have more severe clinical outcomes to infectious diseases, how infectious 
agents affect the fetus and pregnancy outcome, and if there is available treatment that could 
benefit pregnant women. 
1.5 FERRET MODEL 
There are several mammalian models for studying influenza and each have their own 
advantages depending on the question being asked35. Mice are commonly used because of their 
low cost, readily available reagents, and the availability of transgenic mice, which allow for the 
study of genetic contributions. However, influenza virus does not naturally replicate in mice and 
therefore, the influenza strains have to be adapted. Mice also do not show similar clinical signs 
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and cannot transmit virus effectively, preventing the possibility of transmission and pathogenesis 
studies.  
 The ferret model is generally considered the only small mammalian model that is well-
suited for the study of the pathobiology of influenza virus35. The ferret has been well established 
for the study of many respiratory viruses such as coronavirus, nipah virus and morbillivirus. The 
general advantages of using ferrets as an animal model are that they are relatively small and 
exhibit numerous clinical features associated with human disease, which is particularly true for 
influenza infection.  This is because ferret and human lung physiology are similar, exhibiting 
similar distribution patterns of the 2,3- and 2,6-linked sialic acid residues which influenza uses as 
its entry receptor36. Furthermore, ferrets have similar respiratory compartments that are ideal for 
determining different areas of disease manifestations. Ferrets are highly susceptible to human 
influenza and can naturally transmit the virus to each other, making them excellent models for 
investigating transmission. Lastly, ferrets are well suited for vaccine efficacy and drug studies 
because they respond in an immunologically similar way to human infection. 
We propose the use of a pregnant ferret model to investigate the immunological and 
virological parameters that led to the disproportionately high morbidity and mortality observed 
among pregnant women during the pH1N1. In the future, this pregnant ferret model could be 
crucial in uncovering the mechanisms as to why pregnant women have poorer clinical outcomes 
during influenza pandemics in comparison to the general population. It could also answer, if 
pH1N1 infection affects or alters the fetus and pregnancy outcome and further, could be useful in 
the evaluation of potential therapeutics.  
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2.0  STATEMENT OF THE PROJECT AND SPECIFIC AIMS 
In April 2009, the World Health Organization (WHO) issued a Global Outbreak Alert as 
a result of laboratory confirmed human cases of Swine Influenza A/H1N1 in the USA and 
Mexico37. Two months later, the U.S. Centers for Disease Control and Prevention (CDC) and 
WHO declared this outbreak of swine H1N1 influenza a pandemic.  Although the global 
infection rate was recently estimated to be 11% to 21%, much lower than previously predicted, 
enhanced surveillance implemented by the CDC for pregnant women in the 2009 pandemic, 
confirmed increased severity of infection and overall higher incidence of influenza infection 
among pregnant women16. These results are consistent with what has been observed in previous 
influenza pandemics and seasonal epidemics.  
There has been little examination of the exact mechanism that is responsible for this 
disproportionate morbidity and mortality. It is believed that pregnancy creates an immune 
modulatory state to prevent rejection of the fetus, but additional investigation of the contribution 
of this condition in the pathogenesis of viruses has not been thoroughly explored30. To this end, a 
pregnant animal model for pH1N1 is necessary to investigate the immunological parameters of 
this disparity and to be able to evaluate possible interventions in the future. 
The ferret model has been well established for the study of influenza virus and has been 
proven to be a good model for studying various aspects of the human disease compared to the 
mouse model35. This is because influenza infection closely resembles that in humans with similar 
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characteristics of clinical signs, pathogenesis and immunity. Also, ferrets are considered a 
natural host for both Type A and B human influenza viruses so strains do not need to be adapted. 
Furthermore, ferrets have other physical characteristics that are similar to humans, such as a long 
trachea and differing respiratory compartments, which are ideal for determining different areas 
of disease manifestation.  
In the last two years, the Stefano-Cole laboratory has worked to develop a pregnant ferret 
model for pandemic 2009 H1N1 using an aerosol challenge method. Timed-pregnant ferrets 
were received at 27d of a 42d gestational period, and exposed to aerosolized H1N1 on d32 to 
simulate the third trimester of pregnancy in humans.  Following infection, all ferrets were 
monitored for clinical signs of disease and tissues were harvested at necropsy for further 
histological and immunological analyses. 
2.1 HYPOTHESIS 
Increased morbidity and mortality has been reported among pregnant women for both 
pandemic and seasonal epidemics of influenza.  However, little is known about the 
mechanism(s) responsible for this disproportionate morbidity and mortality. We have established 
a pregnant ferret model for evaluation of 2009 H1N1 influenza infection during late stage 
pregnancy.  The goal of this project is to evaluate clinical, viral and immunologic parameters 
associated with increased morbidity and mortality in pregnant ferrets infected with aerosolized 
H1N1.  Our working hypothesis was that increased morbidity and mortality observed with H1N1 
infection during late stage pregnancy is due to differences in early immune responses rather than 
quantitative levels of virus replication and dissemination. 
 12 
2.1.1 Specific Aim 1: To compare quantitative viral loads and viral dissemination 
between pregnant and non-pregnant ferrets.  
To compare quantitative viral loads and tissue dissemination between pregnant and non-
pregnant ferrets we used quantitative reverse transcriptase real-time polymerase chain reaction 
(rRT-PCR) to detect viral copies in lung, spleen, liver, brain, fetal brain, fetus, placenta, uterus, 
and plasma. Also, our pathologist (T.D.O.), characterized pathological changes associated with 
H1N1 infection from the tissues harvested at necropsy.  
2.1.2 Specific Aim 2: To elucidate differences in innate immunity elicited by H1N1 
infection in pregnant and non-pregnant ferrets. 
To obtain mRNA levels in lung, spleen, placenta, uterus and fetus we used semi-
quantitative real-time polymerase chain reaction (RT-PCR) to detect interferon-α (IFN-α), 
interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), interleukin-10 (IL-
10), interleukin-12p40 (IL-12p40), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). 
To calculate the fold change we used the (ΔΔCycle threshold ΔΔCt) method by standardizing to 
GAPDH levels and comparing back to baseline (Day 0) levels. We also, monitored the 
development of antibody responses over the course infection by hemagglutination inhibition 




3.0  METHODS AND MATERIALS 
3.1 FERRET STUDY 
Eight of each 2009 H1N1 sero-negative, timed pregnant (received on day 27 of an 
approximate 42 day gestation) and control (non-pregnant) ferrets were received from Triple F 
Farms (Sayre, PA). Ferrets were housed in ABSL-2 containment for the duration of the study. 
Research was conducted at the University of Pittsburgh and was in compliance with the Animal 
Welfare Act and other federal statutes and regulations relating to animals and experiments 
involving animals. The University of Pittsburgh is fully accredited by the Association for 
Assessment and Accreditation of Laboratory Animal Care International.  
All ferrets rested for 24 hours after transport prior to subcutaneous implantation of IPTT-
300 temperature chips (BioMedic Data Systems, Seaford, DE).   Ferrets were allowed to 
acclimate for an additional 4 days prior to challenge with aerosolized 2009 H1N1.  Immediately 
following challenge (day 0), two each non-pregnant (control) and pregnant ferrets were 
sacrificed and tissues were harvested for subsequent pathologic and virologic analysis.  On days 
3, 5, and 7 post-challenge, two ferrets in each the control and pregnant cohorts were again 
sacrificed to monitor the progression of infection in vivo (Table 1).  All ferrets were monitored 
daily for weights and body temperatures prior to and after infectious challenge.  Clinical signs of 
infection that included lethargy, reduced food and water intake, changes in behavior, nasal 
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discharge, sneezing, labored breathing and spontaneous premature delivery were also observed.  
Ferrets that became moribund (defined as >25% weight loss, clinical signs or combination of 
both) were euthanized promptly.  All harvested tissues were flash frozen in liquid nitrogen or 
stored in 2% formalin at -80°C.  
 
Table 1. Ferret Serial Sacrifice Study 
 
 
3.2 VIRUS PROPAGATION AND INNCOLATION INTO FERRETS 
3.2.1 Virus 
A high titer stock of 2009 H1N1 influenza (A/California/04/09) was grown in MDCK 
cells using the procedure described in the Appendix and frozen at -80oC until use. Titer was 
confirmed by incubation with MDCK cells to evaluate cytopathic effect in a TCID50 assay using 
the Reed-Muench formula38 and confirmed by hemagglutination with turkey erythrocytes 
(Lampire Biologicals).   
Pregnant  Non-pregnant 
ID Number  Day Sacrificed ID Number Day Sacrificed 
97-11 0 112-11 0 
100-11 0 107-11 0 
98-11 3 105-11 3 
103-11 3 110-11 3 
99-11 5 111-11 5 
102-11 5 108-11 5 
101-11 7 106-11 7 
104-11 7 109-11 7 
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3.2.2 Aerosol challenge 
Aerosols containing influenza virus were generated using a Collison 3-jet nebulizer 
(BGI®, Waltham, MA) controlled by the AeroMP system (Biaera Technologies, Hagerstown, 
MD) inside a class III biological safety cabinet (Baker Co., Sanford, ME). Ferrets were exposed 
in groups of 4 (two pregnant, two control ferrets) for 10 minutes to aerosolized influenza virus in 
a whole-body exposure chamber (Biaera Technologies). Presented dose was determined from 
aerosol samples collected in an all-glass impinger (AGI) containing 10 ml of DMEM and 0.5% 
BSA. Using Guyton’s formula for respiratory minute volume, the presented dose was estimated 
to be 1504 ± 339 TCID50 of pH1N1. 
3.3 QUANTITATIVE REVERSE TRANSCRIPTASE REAL TIME POLYMERASE 
CHAIN REACTION (rRT-PCR) 
3.3.1 RNA Extraction and Primer Design 
Lung, liver, spleen, placenta, uterus, fetus, brain and plasma of 2 ferrets per group 
(pregnant and no pregnant) were harvested at 0, 3, 5 and 7 days post infection (D.P.I.). Tissue 
homogenates and plasma were used for PCR analysis. From each tissue 100mg was 
homogenized and RNA extracted using TRI Reagent (Ambien, Grand Island, NY). Following 
the manufactures guidelines RNA was further purified using the MagMAX-96 for Microarrays 
Kit (Ambion, Grand Island, NY) by the spin procedure. One-step quantitative real-time reverse 
transcription-PCR was performed following the protocol established by the WHO Collaborating 
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Centre for influenza using the Invitrogen Superscript III Platinum One-Step Quantitative Kit 
(Invitrogen, Carlsbad, CA) based on the detection of the H1N1 matrix and nucleoprotein gene 
listed in Appendix Table 3 (Biosearch Technologies, Inc., Novato, CA)39. Controls and a 
standard curve (series of twofold dilutions starting with 3 x 106 A/California/04/09) were 
included from viral stocks and day 0 tissue samples.  Standard curve cycle threshold (CT) values 
began at ~16 for both primer sets and each dilution was ~ 2.5 cycle thresholds above the next. 
3.3.2 PCR 
Samples were analyzed by real-time PCR with a 7900HT Fast Real-Time PCR system 
(Applied Biosystems, Carlsbad, CA) for 40 cycles using the PCR reagents listed in Table 4. 
When all controls met the expected results, the sample was considered positive for pH1N1 if 
both reaction growth curves crossed the threshold line within 40 cycles using a thermocycler 
program listed in Table 5.  
3.4 HISTOLOGICAL ANALYSIS 
All tissues were harvested immediately following sacrifice of each animal, and preserved 
in 2% formalin at -80oC. Six micron thick sections of tissues were stained with hematoxylin and 
eosin and evaluated for pathology by a board certified anatomic pathologist (T.D.O). 
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3.5 QUANTIFICATION OF MRNA 
3.5.1 RNA Extraction, cDNA synthesis and Primer Design 
RNA isolation was performed on ferret lungs, spleen, fetus, placenta and uterus using the 
RNeasy Mini Kit and on-column DNase digestion protocols (Qiagen). First strand cDNA 
synthesis was performed using 0.5μg RNA and Maxima First Strand cDNA Synthesis kit 
(Thermo Scientific, Hanover Park, IL). Primer sequences for interferon (IFN) γ, IFN-α, tumor 
necrosis factor (TNF) α interleukin (IL) 6, IL-10, IL-12p40 and GAPDH (Integrated DNA 
Technologies, Coralville, IA) were published elsewhere40,41 and are listed in Appendix Table 6.  
3.5.2 PCR 
Semiquantitative reverse-transcription polymerase chain reaction was performed using 
0.5μg of RNA, Maxima SYBR Green qPCR Master Mix (Thermo Scientific, Hanover Park, IL) 
and an Bio-Rad MiniOpticon using the protocol listed in Table 7 and Gene Expression program 
in Table 8. Expression levels were normalized to Glyceraldehyde-3-Phosphate Dehydrogenase  
(GAPDH) and are reported as fold change compared with day 0 animals based on the ΔΔCt 
method. To obtain the ΔCt, GAPDH Ct value was subtracted from the gene of interest at each 
time point. The fold change was calculated by subtracting the day 0 ΔCt values from the 
subsequent days ΔCt values. To obtain these values as absolute values, the formula, fold change 
= 2 –ΔΔCT was used42. 
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3.6 SEROLOGICAL ANALYSIS 
Whole blood samples collected from each ferret were processed to sera by allowing clot 
formation at room temperature for 30 minutes followed by clot removal by centrifugation at 
1,000 x g for 10 minutes at 4°C. Serum was further absorbed using 0.5% Turkey red blood cells 
(TRBCs) (Lampire Biological Labs, Pipersville, PA) and heat inactivated at 57℃ for 30 minutes. 
A hemagglutination inhibition assay (HAI) was used to determine antibody titers using 1% 
TRBCs. HAI assay detects the serum antibodies to the viral hemagglutinin by measuring the 
inhibition of virus-mediated agglutination of turkey erthyocytes. Briefly, TRBCs were washed 
with 1X PBS and resuspended to a final concentration of 1% TRBCs/volume. In 96 vee-bottom 
plates, serum was first serially diluted (twofold) in the plate in duplicate columns. Virus was 
diluted to contain four agglutinating units in sterile PBS and added to all wells except for the 
negative control column. Plates were then incubated for 30 minutes and agglutination was 
observed. Nonagglutinating cells are defined as having all cells drop to the bottom forming a 
button whereas agglutinating cells didn’t settle to the bottom but instead formed a lattice. The 









4.0  RESULTS 
Sixteen influenza sero-negative age-matched control ferrets and timed-pregnant ferrets 
were received on day 27 of a 42-day gestational period. Both ferret groups were allowed to 
acclimate for 5 days and then aerosol challenged with pandemic H1N1. The timed-pregnant 
ferret group was challenged on gestational day 32 to stimulate beginning of third trimester for 
the pregnant ferrets. Two ferrets from each group were serially sacrificed and tissues were taken 
on day 0 (immediately post-infection), day 3, day 5 and day 7. Temperature, weight and clinical 
signs were monitored prior to and throughout infection. 
4.1 CLINICAL MONITORING POST INFECTION 
Temperature in both groups, pregnant and non-pregnant peaked at 1-2 days post infection 
(D.P.I.) and subsequently returned to the normal range by day 3 PI (Figure 1A). The pregnant 
ferret group displayed greater weight loss continuously over the course of infection compared to 
the non-pregnant ferret group that returned to baseline weight by day 3 PI (Figure 1B).  Weight 
loss continuously throughout infection in the pregnant ferret group is particularly alarming 
because the start of the 3rd trimester is typically when the most weight is gained. The pregnant 
ferret group also displayed more severe clinical signs compared to the non-pregnant infected 
 20 
ferret group such as greater lethargy, reduced food and water intake, nasal discharge with 
sneezing, as well as labored breathing by day 3-7 PI (Figure 1C). 
 
 
Figure 1. Clinical signs of non-pregnant and pregnant ferrets after aerosol exposure to A/California/04/09 
during serial sacrifice study.  
Eight pregnant ferrets at day 33 gestation and eight non-pregnant ferrets were aerosol exposed to 1.75 x 104 pfu 
A/California/04/09. Two ferrets from each group were serially sacrificed on day 0 (immediately after exposure), day 
3, day 5 and day 7. (A) Temperature change of pregnant and non-pregnant ferrets over the course of infection. (B) 
Percentage weight change of pregnant and non-pregnant ferrets over the course of infection. (C) Clinical Score 
based on each ferrets behavior, appearance, temperature and weight change over the course of infection. Means are 
shown with standard deviation (SD) for each time point. 
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4.2 SPECIFIC AIM 1: TO COMPARE QUANTITATIVE VIRAL LOADS AND 
VIRAL DISSEMINATION BETWEEN PREGNANT AND NON-PREGNANT FERRETS 
4.2.1 Viral Dissemination and Load 
To test whether differences in dissemination and/or viral load contributed to the more 
severe clinical outcomes in the pregnant ferret group compared to the non-pregnant group we 
used semi-quantitative reverse transcriptase RT-PCR to detect viral copy levels in tissues. 
Tissues tested included lung, brain, placenta, uterus, fetus, spleen, liver, heart and fetal brain. 
Data will be displayed in two forms, in panel A by dot plot and panel B a box plot. Formal 











4.2.1.1  Lung 
Viral copies were detected at similar levels immediately post challenge in both the 
pregnant and non-pregnant ferret group (Figure 2). In the lung, viral copies peaked at day 3 PI 
and gradually decreased on day 5 and 7 PI in both pregnant and non-pregnant groups.  
 
Figure 2. Tissue dissemination and viral loads in lungs of pregnant and non-pregnant ferrets infected with 
A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Samples of 
lung were used for RNA isolation to determine viral load by quantitative rRT-PCR. Viral copies were determined by 
the standard curve method using two separate primers (universal InfA primer and swine InfA primer). (A) Viral 
copies determined in lung homogenates of each primer set in pregnant (grey dots) and non-pregnant ferrets (black 
dots) shown as a dot plot with mean and SD. (B) Viral copies determined in lung of each ferret group shown as a 








Virus was also detected in the brains of most ferrets by day 3 PI and remained at a 
continuous level for the duration of the study in both pregnant and non-pregnant ferret groups 
(Figure 3). One of two ferrets in the non-pregnant group on days 5 and 7 PI were negative for 
both primer sets against pH1N1. This result indicates that aerosol challenge of pH1N1 is able to 
progress up the olfactory bulb or possible disseminate through central nervous system. 
 
Figure 3. Tissue dissemination and viral loads in brains of pregnant and non-pregnant ferrets infected with 
A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Samples of 
brain were used for RNA isolation to determine viral load by quantitative rRT-PCR. Viral copies were determined 
by the standard curve method using two separate primers (universal InfA primer and swine InfA primer). (A) Viral 
copies determined in brains homogenates of each primer set in pregnant (grey dots) and non-pregnant ferrets (black 
dots) shown as a dot plot with mean and SD. (B) Viral copies determined in brains of each ferret group shown as a 
box and whiskers plot with mean and SD. 
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4.2.1.3 Placenta and Uterus 
Low levels of pH1N1 viral copies were detected in the placenta of the pregnant ferrets by 
day 3 PI and consistently found throughout the course of infection (Figure 4). No viral copies 
were found in the uterus tissue of non-pregnant ferret groups. 
 
Figure 4. Tissue dissemination and viral loads in placentas of pregnant and uteruses of non-pregnant ferrets 
infected with A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Samples of 
placentas and uteruses were used for RNA isolation to determine viral load by quantitative rRT-PCR. Viral copies 
were determined by the standard curve method using two separate primers (universal InfA primer and swine InfA 
primer). (A) Viral copies determined in placenta and uterus homogenates of each primer set in pregnant (grey dots) 
and non-pregnant ferrets (black dots) shown as a dot plot with mean and SD. (B) Viral copies determined in placenta 





Quantifiable pH1N1 viral copies were detected in the fetus of both pregnant ferrets at day 
7 PI at low levels (Figure 5).  Fetal brain was also tested for viral presence but no detectable 
levels of pH1N1 were present.  
 
Figure 5. Tissue dissemination and viral loads in fetus of pregnant and non-pregnant ferrets infected with 
A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Samples of 
fetal tissue were used for RNA isolation to determine viral load by quantitative rRT-PCR. Viral copies were 
determined by the standard curve method using two separate primers (universal InfA primer and swine InfA primer). 
(A) Viral copies determined in fetal homogenates of each primer set of pregnant (grey dots) shown as a dot plot with 






Histologic analyses of tissues sections from the ferrets revealed that most pathologic 
changes were observed in the lung (Figure 6). Lungs in both pregnant and non-pregnant groups 
had fluctuating levels of pulmonary alveolar proteinosis at different time points (Table 2). 
Beginning at day 3 PI and extending throughout infection in both the pregnant and non-pregnant 
ferrets groups displayed larger bronchi and an accumulation of foamy macrophages (Figure 6). 
By day 5 and 7 PI the larger airways became plugged with necrotic debris, residual inflammatory 
cells, peri-bronchial and perivascular lymphatic inflammation. A summary of the pulmonary 
changes is shown in Table 2. No obvious pathologic changes were distinguishable between the 
pregnant and non-pregnant ferret groups.  
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 Figure 6. Histologic images of lung sections showing prominent pathologic responses after aerosol infection 
with H1N1 2009 influenza. 
(A) Lung section from non-pregnant ferret at day 0 showing areas of normal alveoli (upper left) adjacent to alveolar 
spaces filled with proteinaceous material (alveolar proteinosis, lower right). Lung section from a pregnant ferret 7 
days after infection showing diffuse pulmonary alveolar proteinosis (B), large airway plugging with mucus and 
inflammatory cells (C), and a bronchial with peribronchial inflammation and plugging with inflammation and 






Table 2. Pathologic changes noted in the lungs of pregnant and non-pregnant ferrets at various time 
points (days) after infection with influenza virus. 
 
Pathologic changes include pulmonary alveolar proteinosis (PAP), plugging of large airways with necrotic debris or 
foamy macrophages, and peri-bronchial and peri-vascular lymphocytic inflammation. Values represent number of 
ferrets with pathology in indicated organ at dose of virus per number of ferrets in the treatment group. 
 
 
No pathologic changes were observed in the liver, heart, spleen, brain, or fetus at any 
time point. No obvious pathology was seen in the placenta, but there may have been a mild 
increase in villi epithelial cell apoptosis at days 5 and 7 post viral exposure (Figure 7).  
 
 
Figure 7. Histologic images of placenta sections showing pathologic responses after aerosol infection with 
H1N1 2009 influenza.  
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(A) Placenta section from pregnant ferret at day 7 showing areas of normal placenta architecture and increased 
magnification on areas of apoptotic bodies (B and C). 
4.2.3 Summary of Aim 1 
In summary, pregnant ferrets demonstrated an increased severity of clinical disease 
highlighted by a greater weight loss and more severe clinical signs relative to non-pregnant 
ferrets. Disease severity in the pregnant ferrets was not due to discernable differences in viral 
dissemination or greater viral burden. In addition, pulmonary pathology observed in both 
pregnant and non-pregnant ferrets was comparable. Viral copies detected in the placenta by 3 
DPI and fetus by 7 DPI suggests possible fetal transmission. Placental pathology included a mild 







4.3 SPECIFIC AIM 2: TO ELUCIDATE DIFFERENCES IN INNATE IMMUNITY 
ELICITED BY H1N1 INFECTION IN PREGNANT AND NON-PREGNANT FERRETS 
4.3.1 mRNA Transcript Levels of Innate Immune Response 
Pregnancy is an immune modulatory state in which host immune response is dampened 
and skewed toward a Th2 response29. To test whether differences in mRNA transcript levels of 
innate immune response genes contributed to the more severe clinical outcomes in the pregnant 
ferret group compared to the non-pregnant group, semi-quantitative RT-PCR using the 
housekeeping gene, GAPDH to quantify transcript levels of interferon (IFN) γ, IFN-α, tumor 
necrosis factor (TNF) α, interleukin (IL) 6, IL-10, and IL-12p40 was used. Tissues tested 
included lung, spleen, placenta, uterus, and fetus.  
Due to initial discrepancies in basal levels of cytokines in the pregnant compared to the 
non-pregnant ferret groups, the following cytokine mRNA levels were graphed using two 
reference groups, we have (a) compared back to each group’s own day 0 reference levels and (b) 
compared both groups back to non-pregnant day 0 to reveal basal cytokine transcript differences. 
4.3.1.1 Lung 
 Pregnant ferrets had lower initial basal levels in lung tissue of IL-6, IFN-γ and IL-10 but 
greater initial levels of IFN-α and TNF-α (Figure 8). Upon infection, pregnant ferrets had 
elevated levels of IL-6, IFN-γ, TNF-α and IL-10 by day 3 and 5 PI compared to the non-pregnant 
ferrets suggesting a heightened pro-inflammatory response. Initial levels of IFN-α and TNF- α 
were higher in the pregnant ferret lungs and peak at day 5 PI before decreasing.  
 31 
  32 
Figure 8. Cytokine levels in lung tissue of pregnant and non-pregnant ferrets infected with 
A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Lung samples 
were assessed for cytokine messenger RNA expression (n=2 per time point) using RT-PCR and are represented as 
the mean fold change shown with standard deviation compared to the values of their own reference group (a) and (b) 
compared to the day 0 non-pregnant ferret group. (A) Interleukin 6 (IL-6) mRNA levels in the lung homogenates of 
pregnant and non-pregnant ferrets compared back to their own group day 0 time point. (B) IL-6 mRNA levels in the 
lung homogenates of pregnant and non- pregnant ferrets compared back to the non-pregnant day 0 time point. (C) 
Interferon α (IFN-α) mRNA levels in the lung homogenates of pregnant and non-pregnant ferrets compared back to 
their own group day 0 time point.  (D) IFN-α mRNA levels in the lung homogenates of pregnant and non-pregnant 
ferrets compared back to the non-pregnant day 0 time point. (E) Interferon γ (IFN-γ) mRNA levels in the lung 
homogenates of pregnant and non-pregnant ferrets compared back to their own group day 0 time point. (F) IFN-γ 
mRNA levels in the lung homogenates of pregnant and non-pregnant ferrets compared back to the non-pregnant day 
0 time point. (G) Tumor necrosis factor α (TNF-α) mRNA levels in the lung homogenates of pregnant and non-
pregnant ferrets compared back to their own group day 0 time point. (H) TNF-α mRNA levels in the lung 
homogenates of pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 time point. (I) 
Interleukin 10 (IL-10) mRNA levels in the lung homogenates of pregnant and non-pregnant ferrets compared back 
to their own group day 0 time point. (J) IL-10 mRNA levels in the lung homogenates of pregnant and non-pregnant 







4.3.1.2  Spleen 
Pregnant ferrets had lower initial basal levels of IL-6, IFN-γ, and IL-12p40 but elevated 
initial levels of IFN-α and IL-10 in spleen tissue compared to non-pregnant day 0 levels (Figure 
9).  IL-6, IFN-γ and IL-12p40 levels in the pregnant ferrets dramatically increased compared to 
pregnant day 0 by day 3 PI levels but were not elevated compared back to the non-pregnant day 
0 reference group. IFN-α levels in pregnant ferrets had high initial levels in the spleen compared 
to the non-pregnant day 0 group but decreased upon infection. IFN-α levels peaked in spleen of 
the non-pregnant ferrets at day 5 PI and subsequently decreased. IL-10 levels in the spleen of 
pregnant ferrets were initially high compared to the non-pregnant reference group but decreased 
steadily over the course of infection whereas the non-pregnant ferret group increased over the 




Figure 9. Cytokine levels in spleen tissue of pregnant and non-pregnant ferrets infected with 
A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Spleen 
samples were assessed for cytokine messenger RNA expression (n=2 per time point) using RT-PCR and are 
represented as the mean fold change (standard deviation) compared to the values of their own reference group (a) 
and (b) compared to the day 0 non-pregnant ferret group. (A) Interleukin 6 (IL-6) mRNA levels in the spleen 
homogenates of pregnant and non-pregnant ferrets compared back to their own group day 0 time point. (B) IL-6 
mRNA levels in the spleen homogenates of pregnant and non- pregnant ferrets compared back to the non-pregnant 
day 0 time point. (C) Interferon α (IFN-α) mRNA levels in the spleen homogenates of pregnant and non-pregnant 
ferrets compared back to their own group day 0 time point.  (D) IFN-α mRNA levels in the spleen homogenates of 
pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 time point. (E) Interferon γ (IFN-γ) 
mRNA levels in the spleen homogenates of pregnant and non-pregnant ferrets compared back to their own group 
day 0 time point. (F) IFN-γ mRNA levels in the spleen homogenates of pregnant and non-pregnant ferrets compared 
back to the non-pregnant day 0 time point. (G) Interleukin 10 (IL-10) mRNA levels in the spleen homogenates of 
pregnant and non-pregnant ferrets compared back to their own group day 0 time point. (H) IL-10 mRNA levels in 
the spleen homogenates of pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 time point. 
(I) Interleukin 12p40 (IL-12p40) mRNA levels in the spleen homogenates of pregnant and non-pregnant ferrets 
compared back to their own group day 0 time point. (J) IL-12p40 mRNA levels in the spleen homogenates of 







4.3.1.3  Placenta and Uterus 
Initially, pregnant ferret placentas had similar levels of IL-6, IFN-γ and IL-12p40, 
elevated levels of IL-10 and lower levels of IFN-α compared to the non-pregnant day 0 uteruses 
(Figure 10). IL-6 levels peaked in the placenta of the pregnant ferrets at day 3 PI and 
subsequently decreased back to initial levels but no change was observed in the uterus of the 
non-pregnant ferrets over the course of infection.  IFN-α and IFN-γ mRNA levels peaked by day 
3 PI in the placenta however compared to the uterus levels did not significantly increase. IL-10 
mRNA levels in the placenta of pregnant ferrets were initially high compared to the non-
pregnant reference group and peaked at day 3 PI. IL-12p40 mRNA levels were not significantly 




Figure 10. Cytokine levels in the placental tissue of pregnant and uterine tissue of non-pregnant ferrets 
infected with A/California/04/09.  
Two ferrets from each of the pregnant and non-pregnant groups on day 0, 3, 5, and 7 were sacrificed. Placenta and 
uterus samples were assessed for cytokine messenger RNA expression (n=2 per time point) using RT-PCR and are 
represented as the mean fold change (standard deviation) compared to the values of their own reference group (a) 
and (b) compared to the day 0 non-pregnant ferret group. (A) Interleukin 6 (IL-6) mRNA levels in the placenta and 
uterus homogenates of pregnant and non-pregnant ferrets compared back to their own group day 0 time point. (B) 
IL-6 mRNA levels in the placenta and uterus homogenates of pregnant and non- pregnant ferrets compared back to 
the non-pregnant day 0 time point. (C) Interferon α (IFN-α) mRNA levels in the placenta and uterus homogenates of 
pregnant and non-pregnant ferrets compared back to their own group day 0 time point.  (D) IFN-α mRNA levels in 
the placenta and uterus homogenates of pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 
time point. (E) Interferon γ (IFN-γ) mRNA levels in the placenta and uterus homogenates of pregnant and non-
pregnant ferrets compared back to their own group day 0 time point. (F) IFN-γ mRNA levels in the placenta and 
uterus homogenates of pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 time point. (G) 
Interleukin 10 (IL-10) mRNA levels in the placenta and uterus homogenates of pregnant and non-pregnant ferrets 
compared back to their own group day 0 time point. (H) IL-10 mRNA levels in the placenta and uterus homogenates 
of pregnant and non-pregnant ferrets compared back to the non-pregnant day 0 time point. (I) Interleukin 12p40 (IL-
12p40) mRNA levels in the placenta and uterus homogenates of pregnant and non-pregnant ferrets compared back 
to their own group day 0 time point. (J) IL-12p40 mRNA levels in the placenta and uterus homogenates of pregnant 






4.3.1.4  Fetus 
Based on the previous IL-6 and IL-10 data from other tissues and the role of IL-6 in fetal 
inflammatory response syndrome we focused on these cytokines in the fetus. IL-6 and IL-10 
mRNA levels in the fetus of the pregnant ferrets increased over pregnant reference placenta at 
day 3 and 5 PI and subsequently decreased to base levels by day 7 PI (Figure 11).  
 
 
Figure 11. Cytokine levels in the fetal tissue of pregnant ferrets infected with A/California/04/09.  
Fetal samples were assessed for cytokine messenger RNA expression (n=2 per time point) using RT-PCR and are 
represented as the mean fold change (standard deviation) compared to the values of their own reference group at day 
0 time point. (A) Interleukin 6 (IL-6) mRNA levels in the fetal homogenates of pregnant ferrets. (B) IL-10 mRNA 




4.3.2 Monitor Development of Antibody Response 
Pregnant and non-pregnant ferrets demonstrated a similar evolution of influenza specific 
antibody titers in sera for the first 7 days post infection (Figure 12). There may be a slight delay 
in onset of antibody titer in the pregnant group at day 3 and 5 PI however by day 7, both groups 
had analogous antibody responses. 
 
 
Figure 12. Serum antibody responses to aerosol exposure of pH1N1.  
Sera collected from pregnant and non-pregnant ferrets post aerosol exposure to pH1N1 was assayed for the presence 
of antibodies using a hemagluttination inhibition assay. 
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4.3.3 Summary of Aim 2 
 Semi-quantitative RT-PCR revealed differences in basal levels of cytokine mRNA levels 
as well as differences in the responses of pregnant versus non-pregnant ferrets over the course of 
infection in the lung, spleen, placenta and fetus. Notably, IL-6 and IL-10 were both found at 
higher mRNA transcript levels in the lung, placenta and fetus but not in the spleen of the 
pregnant ferrets compared to the non-pregnant ferrets. Alternatively, IFN-γ displayed similar 
transcript levels in both the pregnant and non-pregnant ferret groups over the course of infection 
in the lung, spleen, placenta and uterus. These differences in cytokine response did not lead to a 
difference in ability between the two cohorts ability to mount an effective humoral immune 
response. 
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5.0  DISCUSSION 
The pregnant ferret group exhibited more severe clinical disease compared to a non-
pregnant ferret control group when challenged with pandemic 2009 H1N1, highlighted by the 
pregnant ferrets’ greater weight loss, lethargy, poor oral intake, and respiratory symptoms 
compared to the non-pregnant ferret group. The greater weight loss experienced by the pregnant 
ferrets was particularly problematic, occurring at a time when they should be gaining weight. 
This may contribute to low fetal birth weight, and possibly premature birth. The observed 
outcomes in pregnant ferrets compared to the age-matched controls paralleled what was seen in 
humans and demonstrates the validity of this animal model.  
The greater severity of clinical manifestations in the pregnant ferrets was not due to a 
larger viral burden or differential dissemination differences. Both ferret groups had similar levels 
of virus present in the lung and brain over the course of infection. Brain dissemination is not 
common after intranasal challenge of influenza infection in the ferret model, but the use of 
aerosol challenge has not been thoroughly investigated. Further experimentation is needed to 
discern the possibility of influenza disseminating to the brain through the central nervous system 
or more likely, entering through the olfactory bulb.  
Vertical transmission of pH1N1 in the pregnant human population was rarely reported 
during the H1N1 pandemic17. Here, viral presence was noted in the placenta and fetus of the 
pregnant ferrets. Due to the inability to accurately measure replication competent virus, it can 
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only be concluded that there are viral copies at this site. It is possible that viral presence at the 
maternal/fetal interface is sufficient to contribute to a difference in immunological response at 
these sites and lead to greater influenza pathogenicity29. Pathology did not reveal any significant 
differences in the lungs between the pregnant and non-pregnant ferret group. These lung 
pathology findings contradict a previous study demonstrating that pH1N1 infection in pregnant 
mice was not due to enhanced viral burden, but associated with lung immunopathology and 
impaired lung repair43. Placental pathology revealed villi apoptosis of the pregnant ferrets at 5 
and 7 PI, suggesting possible immune activation or the start of preterm delivery.  
Interestingly, IL-6 and IL-10 were up-regulated at the mRNA gene expression level in the 
pregnant ferret group compared to the non-pregnant ferret group in the lung and at the 
maternal/fetal interface, but not in the spleen. IL-6 is a Th2 pro-inflammatory cytokine that can 
be induced by inflammatory stimuli, and IL-10 is a major immune modulatory cytokine mainly 
thought to suppress Th1 cytokine production. Both IL-6 and IL-10 mainly act via through the 
Janus (Jaks) and STAT signal transduction pathways and share some common biological 
activities44,45. IL-6 can induce expression of IL-10 to some extent,46 and work in concert to clear 
pathogens and regulate cellular immune responses, which are critical to host protection but can 
result in destructive tissue inflammation.  
IL-6 has previously been linked to an increased inflammatory response in humans to 
seasonal influenza infection including high fever, phagocytic cell recruitment, and blood vessel 
permeability47–49. Increased cytokine production upon pH1N1 infection in humans has been 
thought to contribute to pathogenesis, and recently it has been demonstrated that high sera 
cytokine levels of IL-6 and IL-10 were found in patients with severe pH1N1 infection compared 
to non-influenza like illness infection patients and healthy controls27,44. Severely infected pH1N1 
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patients generally had pulmonary inflammation leading to acute respiratory distress and death. 
Further IL-6 production has been postulated as a potential biomarker for severe disease caused 
by pH1N1. The mechanism for IL-6 contributing to disease progression during pH1N1infection 
was preliminarily investigated using an IL-6 -/- mouse model, but did not result in a clear 
mechanism28. IL-6 -/- mice did not demonstrate significant difference in survival or weight loss 
compared to wild type, nor were any differences found in viral loads or lung pathology. 
Similarly, we found higher mRNA levels of IL-6 and IL-10 in the lung, but paradoxically, no 
significant differences were observed in lung pathology between the two groups. This suggests 
another mechanism apart from pulmonary inflammation, leading to pulmonary damage.  
IL-6 and IL-10 levels were also higher in the placentas of the pregnant ferrets compared 
to the uterus of the non-pregnant ferrets, and these cytokines were found in the fetus of the 
pregnant ferrets by day 3 PI and continuing throughout infection. This observation, along with 
mild pathology observed in the placenta, suggests that pH1N1 infection during late stage 
pregnancy elicits a pro-inflammatory response at the maternal/fetal interface that could lead to 
placental damage, abortion, or preterm labor. Previous studies have indicated that TNF-α, IFN-γ, 
IL-12, and IL-6 production during pregnancy can activate the maternal immune system, and lead 
to poor pregnancy outcomes29.  Conceivably, pregnant women infected with pH1N1 could 
activate a detrimental immune response at the maternal/fetal interface, contributing to increased 
rates of premature birth and abortive pregnancy.  
The dysregulation of cytokine response in the pregnant ferrets as compared to the non-
pregnant ferrets did not result in differences in antibody responses. Both groups had comparable 
antibody titers by day 5 PI.  
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To conclude, pregnant ferrets demonstrated a greater clinical course of disease compared 
to the age-matched controls, but this was not due to differences in viral loads, viral 
dissemination, lung pathology, or antibody responses. Differences in mRNA cytokine levels in 
the lung and at the maternal/fetal interface suggest that pregnant ferrets have a dysregulated 
cytokine response, most notably an up-regulation of IL-6 and IL-10.  It could be postulated that 
the difference in cytokine milieu, especially in the initial stages of infection, could lead to a 
differential response where pregnant ferrets could have a less effective cell-mediated and/or 
natural killer (NK) cell response, resulting in more severe disease. Historically, IL-6 and IL-10 
have been implicated in severe pH1N1 infection, suggesting that IL-6 could increase vascular 
permeability causing more significant disease in the lungs of the pregnant ferrets49. IL-6 could 
also activate the maternal and fetal immune response leading to poor gestational outcomes.  
5.1.1 Hypothesized Model 
If the pregnant ferret model accurately mimics pH1N1 infection in pregnant humans, it 
could be postulated that pregnancy creates a skewed immune response, in which the initial 
response to pH1N1 virus is first recognized by the innate immune system, leading to an 
abnormal release of pro-inflammatory cytokines in lung, placenta, and fetal tissue. The 
production of IL-6 and IL-10 in these tissues may lead to disease progression by an unknown 
mechanism. IL-6 and IL-10 induction have been well documented in severe pH1N1 infection, 
leading to acute respiratory distress and possibly death, although the mouse model has not been 
linked with greater pathology in the lung. Further investigation on the underlying mechanism of 
disease progression is necessary. Furthermore, IL-6 has been implicated in premature birth and 
other adverse maternal/fetal outcomes, suggesting that activation of an immune response at the 
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fetal /maternal interface could contribute to poor outcomes such as those seen during the H1N1 
pandemic29.  
We propose an influenza infection model where upon infection with pH1N1 in pregnant 
women induces a dysregulated cytokine response in lungs and at the maternal/fetal interface, 
leading to negative outcomes for the mother and fetus (Figure 13). This abnormal immune 
response does not lead to significantly different viral load or dissemination, or lung pathology 
changes, but may lead to vascular permeability in the lungs, or a less effective cell-mediated 






Figure 13. Hypothesized Model.  
Both pregnant and non-pregnant ferret groups had comparable viral copies (green) and pathology (red lightening) in 
the lung (light blue). Pregnant ferrets had low levels of viral copies (green) present in the placenta by day 3 PI and 
fetus by day 7 PI with mild villi apoptosis present (red lightening). Placenta and fetus also demonstrated higher 




5.1.2 Future Directions 
This study is limited by small sample sizes and a lack of pregnant controls not exposed to 
influenza to provide a natural history comparison during pregnancy.  Future studies that address 
both these limitations will enhance the quality of the findings and further elucidate the noted 
clinical differences. Monitoring a natural history of the disease would help determine if pregnant 
ferrets have greater clinical disease leading to fatal outcomes and/or poor gestational outcomes 
similar to humans. A larger serial sacrifice study would aid in dissecting the mechanism(s) 
responsible for increased severity of clinical disease in pregnant ferrets by further investigating 
immunopathology and immune responses.  Lastly, experiments would be aimed at assessing the 
basic therapeutic questions of when, and what, will best ameliorate the effects of disease, 
especially during pregnancy. 
5.1.3 Public Health Significance 
It is essential that non-traditional animal models be established to answer important 
public health questions. For influenza infection, important non-traditional animal models could 
assist in answering fundamental questions about why the young, elderly and pregnant women are 
more severely affected. Pandemic H1N1 reminded the public health community that little is 
known about the mechanism by which pregnant women are more severely affected and/or more 
susceptible to certain infectious diseases. By establishing pertinent animal models, questions of 
why pregnant women are more susceptible or have more severe clinical outcomes and how viral 
infections affect the fetus and pregnancy outcome could be investigated.  
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Influenza vaccination coverage among pregnant women has been historically low, 
generally <10% of the population, and especially insufficient when compared to other groups 
with increased risk for complications50.  However, in 2009, with the emergence of pH1N1, 
coverage rates jumped to 45% in the United States, still highlighting a substantial coverage gap 
and illustrating the need for therapeutics50. Pregnant women represented 6.3% of 
hospitalizations, 5.9% ICU admissions, and 5.7% of pH1N1 deaths in the United States while 
only making up approximately 1% of the population17. Importantly, an animal model could 
answer translational questions about the effectiveness of therapeutics and when treatment would 






A. Materials and equipment 
• Pipettes 
• MDCK cells (ATCC CCL-34)  
 Currently in LN2 storage (KSC – Box 4B Row D 3/6/09 AH) 
• MDCK maintenance media 
500ml  D-MEM (with 4.5 g/L glucose, 4mM L-glutamine 
#10-017 CV Mediatech or 11965-092 Gibco) 
5ml   Penicillin/Streptomycin (10,000U/ml/10,000 ug/ml) 
5ml  HEPES Buffer (1M stock) 
5ml  L-glutamine, 200 mM (100X) (if needed) 
25ml  Heat Inactivated FBS 
• Virus Dilution Media 
500ml   D-MEM (with 4.5 g/L glucose, 4mM L-glutamine) 
5ml   Penicillin/Streptomycin (10,000 U/ml / 10,000 ug/ml) 
12.5ml  Bovine Serum Albumin fraction V, 7.5% solution in PBS 
5ml  HEPES Buffer (1M stock) 
• Viral Growth Media (Virus Dilution Media + TPCK trypsin) 
100ml   Virus Dilution Media 
0.1ml 1:1000 2mg/ml TPCK-trypsin (2µg/ml) stock added at time 
of use 
Stock: dissolve 20mg TPCK trypsin (type XIII from bovine 
Pancreas) in 10ml of dH20, sterile filter through 0.2 µm 
membrane, store at -20°C. 
• 2x DMEM media 
DMEM powder (Gibco 31600-034, w/ L-glutamine, sodium pyruvate, 
pyridoxine HCl) 
 51 
Hi-Glucose Glucose (4.5g/L total, if low glucose (1g/L) is used, add 
3.5g/L extra) 
NaHCO3 (3.7g/L) 
Prepare as double concentrated liquid, ½ volume of water for dry 
ingredients 
pH to 7.4 
Sterile filter and store at 4°C 
 
• 2% Agarose solution 
Autoclave sterile 2% agarose (Invitrogen, Ultra-pure, 15510-027) in 
MQH20. Store at room temperature. 
• Freezing media 
  50% FBS 
  40% DMEM 
  10% cell culture grade DMSO 
  Sterile filter and store aliquots at -20°C 
• Phosphate buffered saline pH 7.2 (PBS) 
• Cell culture grade trypsin-EDTA solution (0.25%) 
• Influenza Viruses 
• A/California/04/09 (H1N1) – obtained from St. Jude Children’s Research 
Hospital. RBL stock 6/18/09, AH 3x106 TCID50/ml p1 in MDCK 
• 5% Turkey RBC solution (Alsever’s), Lampire Biolabs # 7249409 
• 0.4 % Trypan Blue solution 
• Hemacytometer 
• Humidified incubator, 37°C, 5% CO2 
• 96 well tissue culture flat bottom plates 
• 96 well tissue culture vee-bottom plates 
• TC-6 well plates 
• T-25,75, 125 cm2 vented flasks 
• Multichannel pipettemen 50-300 µl, 5-50 µl 
• Class II Biological safety cabinet 
• Inverted phase contrast microscope 
B. MDCK cells propagation 
i. Thaw cells/initiate culture 
1. Quick thaw cells from LN2 in 37 °C water bath. 
2. Resuspend in 10ml maintenance media 
3. Centrifuge 400g for 5 minutes  
4. Dump supernatant 
5. Resuspend in 8ml maintenance media 
6. Add cell suspension to T25 flask with vented cap 
7. Incubate for 24-36 hrs. at 37°C/5% CO2 
ii. Maintenance/splitting 
1. Cells should be split 1:10 every 3-4 days 
2. Dump growth media 
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3. Wash cells twice with PBS (warmed to 37°C) 
4. Add 0.25% trypsin/EDTA (warmed to 37°C) 
 2ml for T75, 4 ml for T150 
5. Place flask in incubator until cells round up and dislodge (4-8min) 
when the flask is tapped from the side 
6. Resuspend cells in 5:1 volume of maintenance media:trypsin 
washing residual cells from flask surface and triturating gently  
7. Dispense 1:10 volume to a fresh flask 
8. Incubate at 37°C/5% CO2 
Note:  MDCK cells should not be used more the passage twenty 
for productive influenza replication 
iii. Freezing  
1. Collect MDCK cells at 80-90% confluency (log phase growth) 
using steps ii.2-6 
2. Count total viable cells using trypan blue assay 
3. Resuspend cells at ~10^7 cells per ml in freezing media 
4. Aliquot 1ml into cryovials 
5. Place aliquots into freezing vessel indicated for 1°C/hour rate 
6. Place vessel into -80°C freezer 
7. After 48-72 hours transfer vials to LN2 for long term storage 
 
C. Preparation of influenza virus stocks in MDCK cells 
i. Split MDCK cells as per maintenance protocol, culturing into multiple 
T-150 flasks (use MDCK cells of passage 5-15 only) 
ii. At ~90% confluency within 24 hours of culture  
iii. Dump supernatant, wash cells 3x with virus growth media 
iv. Dilute inoculating virus to 0.1-10 moi (depending on strain of virus) in 
2ml of virus growth media for each flask 
1.  Assume ~10^7 MDCK cells at 90% confluency in T-150 
v. Apply virus to MDCK monolayer in flask 
vi. Incubate for 45 minutes at 37°C/5%CO2, rocking the flask every 
10minutes to distribute the inoculum 
vii. Add 60ml virus growth media to the flasks 
viii. Incubate at 37°C/5%CO2 until 3-4 CPE is observe (dependent on virus 
strain, non CPE viruses may be harvested ~48-72 hours) 
ix. Add 2.5ml 7.5% BSA to each flask (0.5% total BSA concentration) 
x. Optional step 1: freeze flask at -80C prior to harvesting supernatant 
1.  Quick thaw on 37C water bath, sonicate sample in flask 
and then proceed to centrifuging sample.  Freeze/thaw and 
sonication may help recover cell associated virus, but could 
reduce infectious free virus.   
xi. Collect supernatant in 50 ml conical tubes and centrifuge 600g x 10 
min at 4°C to pellet debris  
xii. Optional step 2: filter supernatant through 0.2 µM filter to obtain virus 
only fluid 
xiii. Dispense supernatant into 1ml cryovials and freeze aliquots at -80°C 
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xiv. Streak 1ml and 0.5ml samples onto BAP for sterility test 
1. Incubate plate for up to 96 hours at 37°C 
2. Anaerobe culture may also be performed if suspect or required 
for lot verification 
xv. Verify titer of frozen stock with TCID50 or HA assays 
D. Hemagglutination (HA) assay 
• Important note to HA assay:  HA subtype and strain (e.g. H1,H3,H5) have 
differential binding affinities to RBCs dependent on the species from which 
the RBCs where obtained.  This is due to the sialic acid residue expression on 
the RBCs.  To date we have used turkey RBCs for A/CA/04/09 H1N1.  Other 
strains would need to be validated for species of RBC to obtain accurate HA 
measurements.  Additionally, u-bottom plates may be preferred to vee-bottom 
depending on species of RBCs used. 
i. Prepare RBCs 
1. Spin 1ml of RBCs at 650RPM, 5min in 15ml tube 
2. Dump supernatant and resuspend in 10ml PBS for 0.5% RBC 
working solution 
ii. Dilute virus samples 
1. Add 100 µl of virus samples to first column of a v-bottom 96 well 
plate 
2. Add 50  µl of room temperature PBS to the remaining wells, 
ensuring that no virus controls have been included 
3. Serial dilute virus 1:2 (50 µl) across the plate with a multichannel 
pipettman disposing of tips between wells 
iii. Add 50 µl of 0.5% RBC solution to every well 
iv. Agitate plate for 20 seconds to mix samples 
v. Incubate 1 hr at room temperate 
vi. Observe agglutination reaction 
1. Button = no agglutination 
2. Hazy matrix = agglutination  
vii. Record endpoint HA titer (last dilution to demonstrate agglutination) 
 
 
E. TCDI50 assay 
i. Prepare MDCK cells from a confluent T-75cm2 flask. 
1. Remove culture media. 
2. Wash cell monolayer with 10ml PBS. 
3. Add 2.0ml 0.25% trypsin-EDTA to monolayer and incubate for ~5 
minutes. 
4. Collect cells in 10 ml of MDCK maintenance media. 
5. Enumerate cell concentration using standard trypan blue staining 
visualized with a hemacytometer. 
6. Dilute cells to 3.0 x 105 c/ml in maintenance media. 
7. Dispense 100 uL (3.0 x 104 cells) into each well of 96 well flat 
bottom plates, 2 samples may be analyzed per plate. 
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8. Incubate at 37°C, 5% CO2 until confluent monolayer is obtained 
(~24-30 hours). 
9. Remove media from MDCK cells using aspiration. 
10. Wash each well with 200 µl of PBS and remove by aspiration. 
11. Add 150 µl of viral growth media to each well containing cells, set 
plates aside. 
ii. Set up virus titrations 
1. Add 180 µl of viral growth media to rows B-H of 96-well sterile v-
bottom plates using multichannel pipetteman. 
2. Add 200 µl of virus sample to each of 5 wells for sample 1 
(columns 1-5), sample 2 (columns 6-10) and 200 µl of assay buffer 
only to column 11 as non-infection control. 
3. Using multichannel pipette transfer 20 µl from row A to row B, 
discard tips. 
4. Mix 20 times using swirling tip action and transfer again 20 µl 
from row B to row C, discard tips. 
5. Repeat dilution down the plate. 
6. Using multichannel pipette transfer 100 µl of each virus dilution to 
MDCK cells in 96 well flat bottom plates. Start at lowest 
concentration (row H) on v-bottom plate and work up using same 
tips. 
7. Incubate plates at 37°C, 5% CO2. 
8. Observe CPE daily and record using attached template. 
CPE 0 = no cytopathic effects observed, same as 
controls 
CPE 1= monolayer intact, rounded up cells on top 
of monolayer with few dead cells 
CPE 2= many dead cells, but monolayer intact 
CPE 3= most cells destroyed, but some remnants of 
monolayer observed 
CPE 4= monolayer completely destroyed 




F.       Hemagglutination assay for detection of virus in TCID50 assay 
i. See HA assay above (B) 
ii. Prepare RBCs as given above 
iii. Dispense 50 µl to each well of a 96-well v-bottom plate 
iv. Transfer 50 µl of supernatant from TCID50 plate to v-bottom plate so 
that all wells are corresponding (i.e. A1 = A1…H12=H12) 
v. Read reaction after 1 hr incubation at room temperature 
vi. Record + or – HA reaction 
vii. Calculate TCID50 using Reed Meunch method where + HA is 
equivalent to + CPE and – HA is equivalent to zero CPE. 
G. Hemagglutination Inhibition assay for detection of influenza specific antibodies  
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i.  Prepare RBCs 
1. Spin 1 mL of RBCs (turkey RBCs of pH1N1) at 650 RPM for 5 
minutes 
2. Dump supernatant and resuspend in 10mL PBS for a 1% working 
concentration 
ii. Prepare Ferret Sera 
1. Place all sera samples into water bath heated to 56 C for 30 
min to heat inactivate  
2. Absorb the sera by adding 0.5% TRBC suspension to each 
microcentrifuge tube making a 1:5 dilution of the original 
sample (i.e. 50uL sera: 200uL TRBC) 
3. Incubate for 30 minutes at RT, mixing the tubes by inverting 
the tube at 10 min intervals 
4. Pellet the TRBC in the tubes by microcentrifuge for 5 seconds 
at 14,000 RPM 
5. Transfer the sera into new microcentrifuge tubes, being careful 
not to disturb the pellet 
iii. Perform HAI Assay 
1. Add 50 uL PBS to all wells in rows B through G of a 96 well 
vee bottom plate and 100uL to all wells in row H (Control 
wells) 
2. Add 100uL of each serum sample to duplicate, adjacent wells 
in row A as well as 100uL of each viral antigen control on each 
plate. 
3. Serial Dilute 1:2 across plate starting with row A and ending in 
row G 
4. After mixing the contents of row G, remove and discard 50 uL 
from row G 
5. Dilute H1N1 virus stock to 4 HAU (1:4 dilution) 
6. Starting at row G and working up to row A, add 50uL of the 
virus stock to each well 
7. Incubate the plate at RT for 30mins 
8. Add 50uL of the 1% TRBC suspension in PBS to all wells 
starting at row H and working up to row A.  
9. Incubate plate for 30-45min at room temperature  
10. Read plates for agglutination  
11. Record endpoint HA titer (last dilution with a visible button) 
 
H. Tissue Homogenization: For preparation of RNA extraction for Viral qPCR 
1. Homogenize Samples in 1 mL of Virus Dilution Media (1-2 g tissue 
into 2mL VDM) 
2. Take 100uL diluted to standard amount of homogenate (100mg) and 
add to 900 uL TRI Reagent (Sigma catalog #T9424).  Allow to sit and 
room temperature. (Save homogenate for other assays label (15mL 
conical) as Ferret #, Tissue, Date) 
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3. Transfer TRI/homogenate to different tube. Label Ferret #, Tissue, 
Date, TRI. 
4. Store at -70C for up to a month 
 
I. RNA Isolation for Viral qPCR using MagMAX-96 Total RNA Isolation Kit 
(Invitrogen catalog # AM1830) 
i. RNA Isolation: 
1. Transfer homogenized sample to a 1.5 mL microcentrifuge tube. Add 
0.1 volumes of BCP (e.g., add 100 μL BCP to 1 mL of homogenate), and 
cap the tube securely. 
2. Vortex at moderate speed for 5–10 seconds. Store the mixture at room 
temperature for 5min. Centrifuge at 12,000 x g for 10 min at 4°C to 
separate the sample mixture into three phases: phenol-BCP on the bottom 
(red), interphase in the center, and aqueous phase on the top (colorless). 
RNA is in the aqueous phase, while DNA and proteins are in the 
interphase and organic phase (phenol-BCP). 
3. Transfer 100 μL of the aqueous phase to a well of the 96-well 
Processing Plate and continue the procedure. 
ii. RNA Purification Using RNA Binding Beads 
 1. Add 50 μL of 100% isopropanol and shake for 1 min on an orbital 
shaker 
 2. Add 10 μL of RNA Binding Beads (vortex before adding) and shake 
for 3 min on an orbital shaker 
 3. Magnetically capture the RNA Binding Beads and discard the 
supernatant 
4. Move the Processing Plate to a magnetic stand to capture the RNA 
Binding Beads.  
Leave the plate on the magnetic stand until the mixture becomes 
transparent, indicating that capture is complete. The capture time depends 
on the magnetic stand used. Using the Ambion 96-Well Magnetic-Ring 
Stand, the capture time is ~1–2 min. Carefully aspirate and discard the 
supernatant without disturbing the beads, and remove the Processing 
Plate from the magnetic stand. To obtain pure RNA, it is important to 
completely remove the supernatant at this step. 
 
J. 10III.B. 
iii. Separation of Aqueous and Organic Phases Spin Procedure 
 
5. Wash twice with 150 μL Wash Solution 1min on an orbital shaker each 
time. 
a. Capture the RNA Binding Beads on a magnetic stand as in the 
previous step. 
b. Carefully aspirate and discard the supernatant without disturbing 
the beads, and remove the Processing Plate from the magnetic 
stand. 
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c. Repeat steps a–b to wash with a second 150 μL of Wash 
Solution. 
6. Move the Processing Plate to the shaker and shake vigorously for 2 
min. 
   7. Dry the beads by shaking for 2 min 
    8. Elute the RNA in 50 μL of Elution Buffer shake vigorously for 3 min  
a. Capture the RNA Binding Beads on a magnetic stand. The 
purified RNA will be in the supernatant. 
b. Transfer the supernatant, which contains the RNA, to a nuclease-
free container appropriate for your application. 
 
 
J.   Quantitative reverse transcriptase real time PCR (qrRT-PCR) for Pandemic H1N1 
Matrix and Nucleoprotein from Tissue Samples 39 
i. Invitrogen SuperScript ™III Platinum ® One-Step Quantitative Kit 
(cat# 11732-020or 11745-100). 
ii. MicroAmp Optical Plates (ABI N801-0560) 
iii. Optical Adhesive covers (ABI #4311975) 
iv. 7900 HT Thermo cycler (ABI) 
v. Nuclease-free plastics  
vi. DEPC treated H20  
Table 3. Matrix and Nucleoprotein Primer and Probes 
Set up PCR reaction: 
1.    Reaction assay mixtures are made as a cocktail and dispensed into the 96-well reaction 
plate. Water and extracted nucleic acid or positive template controls are then added to the 
appropriate test reactions and controls. 
2.  Label one 1.5 ml microcentrifuge tube for each primer/probe set. 
3.  Determine the number of reactions (N) to set up per assay. It is necessary to make excess 
Primers and 
Probes Sequence (5’>3’) 
Working 
Concentration 
InfA Forward GAC CRA TCC TGT CAC CTC TGA C 40 μM 
InfA Reverse AGG GCA TTY TGG ACA AAK CGT CTA 40 μM 
InfA Probe TGC AGT CCT CGC TCA CTG GGC ACG 10 μM 
SW InfA 
Forward GCA CGG TCA GCA CTT ATY CTR AG 40 μM 
SW InfA 
Reverse GTG RGC TGG GTT TTC ATT TGG TC 40 μM 
SW InfA 
Probe 
CYA CTG CAA GCC CA”T” ACA CAC AAG 
CAG GCA 10 μM 
   Taqman probes are labeled at the 5'-end with the reporter molecule 6-carboxyfluorescein 
FAM) and quenched internally at a modified “T” residue with BHQ1, with a modified 3’- 
end to prevent probe extension by Taq polymerase (Biosearch 
Technologies, Inc.,.Novato, CA).  
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reaction cocktail to allow for the NTC, PTC, HSC reactions and pipetting error. See 
below: 
4.  If number of samples (n) including controls = 1 to 14, then N = n + 1 
5.  If number of samples (n) including controls > 15, then N = n + 2 
6.  Master Mix: calculate the amount of each reagent to be added for each primer/probe set 
reaction master mix. The calculations are as follows: 
Table 4. PCR Reagents for Viral qrRT-PCR 
Reagent  Volume of Reagent Added per Reaction 
Nuclease-free Water  N x 5.5 μl 
Forward Primer  N x 0.5 μl 
Reverse Primer  N x 0.5 μl 
Probe  N x 0.5 μl 
SuperScript™ III RT/Platinum® Taq Mix  N x 0.5 μl 
2X PCR Master Mix  N x 12.5 μl 
Total Volume  N x 20.0 μl 
After addition of the water, mix reaction mixtures by pipetting up and down. Do not 
vortex. 
 
7.   Centrifuge for 5 sec to collect contents at bottom of the tube, and then place the 
tube in cold rack. 
8.   Set up reaction strip tubes or plates in 96-well cooler rack. 
9. Dispense 20uL of each master mix into each well as needed.  
10. Before moving the plate to the nucleic acid handling area, set up the NTC 
reactions for column 1 in the assay set-up area. Add 5 uL of nuclease free water as the 
negative control wells.  
11.Cover the reaction plate and move the reaction plate to the nucleic acid handling 
area. 
12.Vortex the tubes containing the samples for 5 sec..  Centrifuge tubes for 5 sec. 
13.Set up the extracted nucleic acid samples in the cold rack. 
14.Pipette 5 uL of samples into the wells labeled for that sample. Change tips after 
each addition. 
15.Cap the column to which the sample has been added. This will help to prevent 
sample cross contamination and enable you to keep track of where you are on the 
plate. 
16.Repeat steps 13-15 for the remaining samples. 
17. Note: for quantitative analysis, Viral standards must run on each plate using 10^6 
– 10^0 copy/well in 1:10 dilutions in duplicate 
18. Perform amplification/analysis  
a. Open Template on 7900HT ABI  
b. Designate standards from SDS software menu 
c. Designate unknowns 
d. Ensure parameters are correct below. 
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Table 5. Influenza Detection Program 
The reaction voume is 25 μL. Program the thermocycler as follows: 
Reverse Transcription  50°C for 30 min   
Taq inhibitor activation 95°C for 2 min   
PCR amplification (40 cycles) 95°C for 15 sec 55°C for 30 sec*   
Fluorescence data (FAM) should be collected during the 55°C incubation step. 
 
 
• Dissociation Curve  




e. Load plate 
f. Start machine 
g. At completion of run, save data as SDS file 
h. Analyze data (compare to standard curve of TCID50). 
 
 
K. RNA Isolation for mRNA semi-quantitative RT-PCR of cytokines using RNeasy 
Mini Kit from Qiagen (cat. # 774104) and  On-column Dnase Digestion (cat.# 
79254) 
1. Tissues: Do not use more than 30 mg tissue. Disrupt the tissue and homogenize 
the lysate in the appropriate volume of Buffer RLT. Centrifuge the lysate for 3 
min at maximum speed. Carefully remove the supernatant by pipetting, and use it 
in step 2.  
2. Add 1 volume of 70% ethanol to the lysate, and mix well by pipetting. Do not 
centrifuge. Proceed immediately to step 3.  
3. Transfer up to 700 uL of the sample, including any precipitate, to an RNeasy 
Mini spin column placed in a 2 ml collection tube (supplied). Close the lid, and 
centrifuge for 15 s at > 8000 x g. Discard the flow through.  
4. Add 350 uL Buffer RW1 to RNeasy column, close lid, centrifuge for 15 s at > 
8000 x . Discard flow-through.  
5. Add 10 uL DNase 1 stock solution to 70uL Buffer RDD. Mix by gently 
inverting the tube. Centrifuge briefly. 
6. Add DNase I incubation mix (80uL) directly to RNeasy column membrane, and 
place on the bench top (20-30C) for 15min. 
7. Add 350 uL Buffer RW1 to RNeasy column, close lid, centrifuge for 15 s at 
>8,000 x g. Discard flow-through. Continue with step 5 RNeasy Mini Kit. 
8. Add 500uL Buffer RPE to the RNeasy spin column. Close the lid, and 
centrifuge for 15 s at >8,000 x g. Discard flow-through. 
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9. Add 500uL Buffer RPE to the RNeasy spin column. Close the lid, and 
centrifuge for 15 s at >8,000 x g. Discard flow-through. 
10. Place the RNeasy spin column in a new 2 mL collection tube (supplied). 
Centrifuge at full speed for 1 min to dry the membrane.  
11. Place the RNeasy spin column in a new 1.5 mL collection tube (supplied). 
Add 30-50uL RNase-free water directly to the spin column membrane. Close 
the lid, and centrifuge for 1 min at >8,000 x g to elute the RNA.  
12. If the expected RNA yield is > 30 ug, repeat step 8 using another 30-50uL of 
RNase-free water, or using the elute from step 7 (if high RNA concentration is 
required), Reuse the collection tube from step 8.  
13. Nanodrop for RNA purity and concentration 
 
L.  cDNA Synethesis for semi-quantitative RT-PCR: Maxima First Strand cDNA 
synthesis kit for RT-PCR Thermo Scientific (cat # K1642) 
The first strand cDNA synthesis reaction can be performed as an individual reaction or as 
a series of parallel reactions with different RNA templates. Therefore, the reaction 
mixture can be prepared by combining reagents individually or a master mix containing 
all of the components for the RT reaction except template RNA. 
After thawing, mix and briefly centrifuge the components of the kit. Store on ice. 
1. Add into a sterile, RNase-free tube on ice in the indicated order: 
5X Reaction Mix              4 μL 
Maxima Enzyme Mix       2 μL 
Template RNA                 1 μg 
Water, nuclease-free to    20 μL 
Total volume                    20 μL 
2. Mix gently and centrifuge. 
3. Incubate for 10 min at 25°C followed by 15 min at 50°C. 
Note. For RNA template amounts greater than 1 μg, prolong the reaction time to 30 min. 
For RNA templates that are GC-rich or have a large amount of secondary structure, the 
reaction temperature can be increased to 65°C. 
4. Terminate the reaction by heating at 85°C for 5 min. 
The product of the first strand cDNA synthesis can be used directly in qPCR or stored at -
20°C for up to one week. For longer storage, -70°C is recommended. Avoid freeze/thaw 
cycles of cDNA. 
 
Needed Controls: 
Negative control reactions should be used to verify the results of the first strand cDNA 
synthesis. 
 Reverse transcriptase minus (RT-) negative control is important in RT-
qPCR reactions to assess for genomic DNA contamination of the RNA sample. 
The control RT- reaction should contain every reagent for the reverse 
transcription reaction except for the Maxima Enzyme Mix. 
 No template control (NTC) is important to assess for reagent 
contamination. The NTC reaction should contain all reagents for the reverse 
transcription reaction except for the RNA template. 
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M.  Maxima SYBR Green/ROX qPCR Master Mix (2x) Thermo Scientific (cat # 
K0221)40,41 
Table 6. Cytokine Ferret Primers 
Primers  Sequence (5’>3’) 
IFNα Foward ATGCTCCTGCGACAAATGAGGAGA 
IFNα  Reverse TTCTGCAGCTGCTTGCTGTCAAAC 
IFNγ Foward CCATCAAGGAAGACATGCTTGTCAGG 
IFNγ Reverse CTGGACCTGCAGATCATTCACAGGAA 
TNFα Forward  TGGAGCTGACAGACAACCAGCTAA 
TNFα Reverse TGATGGTGTGGGTAAGGAGCACAT 
IL6 Forward CAAATGTGAAGACAGCAAGGAGGCA 
IL6 Reverse TCTGAAACTCCTGAAGACCGGTAGTG 
IL10 Forward TCCTTGCTGGAGGACTTTAAGGGT 
IL10 Reverse TCCACCGCCTTGCTCTTATTCTCA 
IL12p40 Forward ATCGAGGTTGTGGTGGGTGCTATT 
IL12p40 Reverse TAGGTTCATGGGTGGGTCTGGTTT 
GAPDH Forward AACATCATCCCTGCTTCCACTGGT 
GAPDH Reverse TGTTGAAGTCGCAGGAGACAACCT 
 
Set up PCR 
1. Gently vortex and briefly centrifuge all solutions after thawing.  
2. Prepare a reaction master mix by adding the following components (except 
template DNA) for each 10 μl reaction to a tube at room temperature: Maxima SYBR 
Green/ROX qPCR Master Mix (2X)* and for each primer set using the reagents listed in 
Table 7 below.  
Table 7. PCR Reagents 
Reagent  Volume of Reagent Added per Reaction 
Maxima SYBR Green 2x N x 5.0 μl 
Forward Primer  N x 0.5 μl (.5 μM) 
Reverse Primer  N x 0.5 μl(.5 μM) 
Template cDNA 1.0 μl 
Nuclease Free Water  N x 3.0 μl 
Total Volume  N x 10.0 μl 
 
3. Mix the master mix thoroughly and dispense appropriate volumes into PCR tubes or plates.  
4. Add template DNA (≤500 ng/reaction) to the individual PCR tubes or wells containing the 
master mix. Note. For two-step RT-qPCR, the volume of the cDNA added from the RT 
reaction should not exceed 10% of the final PCR volume.  
5. Gently mix the reactions without creating bubbles (do not vortex). Centrifuge briefly if 
needed. Bubbles will interfere with fluorescence detection.  
 62 
 
Table 8. Gene Expression Program 
The reaction volume is 10 μL. Program the thermocycler as follows: 
Denaturation   95°C for 15 min   
PCR amplification (40 cycles) 
95°C for 5s 
60°C for 15 sec 
72°C for 25 sec*   
* SYBR Green data should be collected during the 72°C incubation step. 
 
7. Expression levels were normalized to Glyceraldehyde-3-Phosphate Dehydrogenase  
(GAPDH) and are reported as fold change compared with day 0 animals based on the 
ΔΔCt method. To obtain the ΔCt, GAPDH Ct value was subtracted from the gene of 
interest at each time point. The fold change is calculated by subtracting the day 0 ΔCt 
values from the subsequent days ΔCt values. To obtain these values as absolute values, 
the formula: fold change = 2 –ΔΔCT is used42. 
 
6. Program the thermal cycler according to the recommendations below, place the samples in 
the cycler as seen below and start the program.  
 
  Needed controls : 
 No template control (NTC) is important to assess for reagent contamination or primer 
dimers. The NTC reaction contains all components except template DNA.  
 Reverse Transcriptase Minus (RT-) control is important in all RT-qPCR experiments to 
assess for RNA sample contamination with genomic DNA. The control RT- reaction contains 
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